• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations.

作者信息

Malinowski H, Marroum P, Uppoor V R, Gillespie W, Ahn H Y, Lockwood P, Henderson J, Baweja R, Hossain M, Fleischer N, Tillman L, Hussain A, Shah V, Dorantes A, Zhu R, Sun H, Kumi K, Machado S, Tammara V, Ong-Chen T E, Mahayni H, Lesko L, Williams R

出版信息

Adv Exp Med Biol. 1997;423:269-88. doi: 10.1007/978-1-4684-6036-0_25.

DOI:10.1007/978-1-4684-6036-0_25
PMID:9269503
Abstract
摘要

相似文献

1
Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations.工业用缓释固体口服剂型指南草案。体外-体内相关性的开发、评估和应用。
Adv Exp Med Biol. 1997;423:269-88. doi: 10.1007/978-1-4684-6036-0_25.
2
Setting dissolution specifications for modified-release dosage forms.
Adv Exp Med Biol. 1997;423:159-66. doi: 10.1007/978-1-4684-6036-0_13.
3
Terminology challenges: defining modified release dosage forms in veterinary medicine.术语挑战：定义兽医医学中的改良释放剂型。
J Pharm Sci. 2010 Aug;99(8):3281-90. doi: 10.1002/jps.22095.
4
Impact of IVIVR on product development.体内体外相关性（IVIVR）对产品开发的影响。
Adv Exp Med Biol. 1997;423:241-59. doi: 10.1007/978-1-4684-6036-0_23.
5
The development of a novel in vitro discriminatory dissolution method for a class I drug in a matrix tablet formulation.一种用于基质片剂制剂中 I 类药物的新型体外区分溶出方法的开发。
Adv Exp Med Biol. 1997;423:217-20. doi: 10.1007/978-1-4684-6036-0_20.
6
Scaleup of oral extended-release dosage forms.口服缓释剂型的放大生产
Pharm Res. 1993 Dec;10(12):1800-5. doi: 10.1023/a:1018946819849.
7
Selection of oral controlled-release drugs: a critical decision for the physician.口服控释药物的选择：医生的关键决策。
South Med J. 1993 Feb;86(2):208-14. doi: 10.1097/00007611-199302000-00013.
8
Best practices for the development, scale-up, and post-approval change control of IR and MR dosage forms in the current quality-by-design paradigm.在当前的质量源于设计范式下，红外（IR）和磁共振（MR）剂型的研发、放大生产及批准后变更控制的最佳实践。
AAPS PharmSciTech. 2014 Jun;15(3):665-93. doi: 10.1208/s12249-014-0087-x. Epub 2014 Mar 1.
9
Investigating in vitro drug release mechanisms inside dosage forms. Monitoring liquid ingress in HPMC hydrophilic matrices using confocal microscopy.
Adv Exp Med Biol. 1997;423:129-35.
10
Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified-release products: workshop summary report.建立确保缓控释产品治疗等效性的科学和监管标准的挑战与机遇：研讨会总结报告。
Eur J Pharm Sci. 2010 May 12;40(2):148-53. doi: 10.1016/j.ejps.2010.03.017. Epub 2010 Mar 27.

引用本文的文献

1
In vitro evaluation of mesalazine enteric-coated tablet dissolution by the reciprocating cylinder method.采用往复圆筒法对美沙拉嗪肠溶片溶出度进行体外评价。
Sci Rep. 2025 Jul 1;15(1):22066. doi: 10.1038/s41598-025-05936-8.
2
Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care.揭开未来的面纱：长效注射用兽药开发的机遇。
Pharmaceutics. 2025 May 8;17(5):626. doi: 10.3390/pharmaceutics17050626.
3
Development of a Physiologically Based Biopharmaceutics Model Report Template: Considerations for Improved Quality in View of Regulatory Submissions.
基于生理学的生物药剂学模型报告模板的开发：鉴于监管提交要求，对提高质量的考量
Mol Pharm. 2025 Jun 2;22(6):2735-2746. doi: 10.1021/acs.molpharmaceut.5c00225. Epub 2025 Apr 29.
4
Novel Methods Developed in Bioequivalence Assays: Patent Review.生物等效性试验中开发的新方法：专利综述
AAPS PharmSciTech. 2025 Mar 26;26(4):91. doi: 10.1208/s12249-025-03079-7.
5
Current State and New Horizons in Applications of Physiologically Based Biopharmaceutics Modeling (PBBM): A Workshop Report.基于生理的生物药剂学建模（PBBM）应用的现状与新视野：研讨会报告
Mol Pharm. 2025 Jan 6;22(1):5-27. doi: 10.1021/acs.molpharmaceut.4c01148. Epub 2024 Dec 16.
6
In vitro-in vivo correlation (IVIVC) development for long-acting injectable drug products based on poly(lactide-co-glycolide).基于聚（丙交酯-乙交酯）的长效注射用药物产品的体外-体内相关性（IVIVC）研究
J Control Release. 2025 Jan 10;377:186-196. doi: 10.1016/j.jconrel.2024.11.021. Epub 2024 Nov 19.
7
Advancements in Ocular Therapy: A Review of Emerging Drug Delivery Approaches and Pharmaceutical Technologies.眼部治疗的进展：新兴药物递送方法和制药技术综述
Pharmaceutics. 2024 Oct 12;16(10):1325. doi: 10.3390/pharmaceutics16101325.
8
Establishment of Dissolution Test Method for Multi-Components in Traditional Chinese Medicine Preparations Based on In Vitro-In Vivo Correlation.基于体内外相关性的中药制剂多成分溶出度试验方法的建立
Pharmaceuticals (Basel). 2024 Aug 14;17(8):1065. doi: 10.3390/ph17081065.
9
Patient-Centric Long-Acting Injectable and Implantable Platforms─An Industrial Perspective.患者为中心的长效注射和植入式平台—工业视角。
Mol Pharm. 2024 Sep 2;21(9):4238-4258. doi: 10.1021/acs.molpharmaceut.4c00665. Epub 2024 Aug 19.
10
Physiologically-Based Pharmacokinetic Modeling and In Vitro-In Vivo Correlation of TV-46000 (Risperidone LAI): Prediction from Dog to Human.基于生理的药代动力学建模及TV-46000（长效利培酮）的体外-体内相关性：从犬到人的预测
Pharmaceutics. 2024 Jul 4;16(7):896. doi: 10.3390/pharmaceutics16070896.